Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

French National Observatory on Infective Endocarditis

NCT03272724 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
1991-01-01
Last updated
2025-09-23

Condition(s) studied

Infective Endocarditis

Study summary

The objective of this observatory is to provide a national database of infective endocarditis, informed by all volunteer centers, using a standardized case report forms.

Such an observatory will describe the clinical profile, microbiological, therapeutic and evolving of infective endocarditis (IE); analyze the risk factors for the disease and its prognosis factors of evolution; describe management practices; evaluate and compare in the real drug treatment strategies (including antibiotics) and surgical.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Major Patient * Supported in one of the participating centers * The application of diagnostic classification criteria of Duke modified by Li is carried out after collection of all the data at the end of the patient's hospitalization. Only patients meeting criteria for definite or possible endocarditis will be included in the analyses. * Registered with the French social security system Exclusion Criteria: • Refusal of the patient to participate.

Primary outcome measure(s)

  • history of heart disease — inclusion
    status of heart valves, pre-existing heart conditions
  • risk factors, medical history — inclusion
    associated diseases
  • origin of infection — period of 3 months before infective endocarditis
    high risk procedures
  • weight — inclusion
    kg
  • height — inclusion
    cm
  • clinical symptoms — inclusion
    cardiac, peripheral and neurological symptoms
  • biological outcomes — inclusion
    blood count
  • microbiological outcomes — inclusion
    identification of infecting organisms
  • diagnostic imaging — inclusion
    description of tyhe imaging tests performed
  • antibiotic therapy — from inclusion to recovery
    antibiotic treatment: type and duration
  • surgical procedures — from inclusion to recovery
    description of surgical procedures

Trial sites (1)

FacilityCityRegionStatus
CHRU Vandœuvre-lès-Nancy France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03272724 on ClinicalTrials.gov ↗ ← All trials in France